1. Home
  2. BCG vs KYNB Comparison

BCG vs KYNB Comparison

Compare BCG & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BCG

Binah Capital Group Inc.

HOLD

Current Price

$1.54

Market Cap

25.4M

Sector

N/A

ML Signal

HOLD

KYNB

Kyntra Bio Inc. Common Stock

N/A

Current Price

$7.25

Market Cap

27.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BCG
KYNB
Founded
2016
1993
Country
United States
United States
Employees
150
34
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.4M
27.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BCG
KYNB
Price
$1.54
$7.25
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
19.7K
37.3K
Earning Date
05-14-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$56.15
$0.15
Revenue Growth
N/A
N/A
52 Week Low
$1.36
$6.32
52 Week High
$3.44
$9.58

Technical Indicators

Market Signals
Indicator
BCG
KYNB
Relative Strength Index (RSI) 39.57 63.00
Support Level $1.50 $6.59
Resistance Level $1.68 $7.95
Average True Range (ATR) 0.08 0.32
MACD 0.01 0.08
Stochastic Oscillator 20.01 72.73

Price Performance

Historical Comparison
BCG
KYNB

About BCG Binah Capital Group Inc.

Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.

About KYNB Kyntra Bio Inc. Common Stock

Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.

Share on Social Networks: